DBV Technologies S.A. (DBVTF)

Market Cap	1.13B +1,068.3%
Revenue (ttm)	5.64M -56.0%
Net Income	-146.95M
EPS	-1.05
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	143,274
Open	4.300
Previous Close	4.800
Day's Range	4.300 - 4.300
52-Week Range	0.000 - 4.800
Beta	-0.22
RSI	n/a
Earnings Date	Apr 30, 2026

About DBV Technologies

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. The company’s product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. Its earlier stage research programs include vaccine for the ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 117
• Stock Exchange: OTCMKTS
• Ticker Symbol: DBVTF

Financial Performance

In 2024, DBV Technologies's revenue was $4.15 million, a decrease of -73.61% compared to the previous year's $15.73 million. Losses were -$113.92 million, 56.6% more than in 2023.